1. Home
  2. FBRX

as of 12-15-2025 10:37am EST

$21.77
+$0.03
+0.14%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).

Chart Type:
Time Range:
Founded: N/A Country:
United States
United States
Employees: N/A City: DALLAS
Market Cap: 253.7M IPO Year: N/A
Target Price: $67.00 AVG Volume (30 days): 120.2K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -4.39 EPS Growth: N/A
52 Week Low/High: $4.90 - $25.97 Next Earning Date: 11-14-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

AI-Powered FBRX Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 16 hours ago

AI Recommendation

hold
Model Accuracy: 65.73%
65.73%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Forte Biosciences Inc. News

FBRX Breaking Stock News: Dive into FBRX Ticker-Specific Updates for Smart Investing

All FBRX News

Share on Social Networks: